Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma.
Casper ES, Schwartz GK, Sugarman A, Leung D, Brennan MF. Casper ES, et al. J Clin Oncol. 1997 May;15(5):2111-7. doi: 10.1200/JCO.1997.15.5.2111. J Clin Oncol. 1997. PMID: 9164225 Clinical Trial.
CONCLUSION: LED can be administered every 2 weeks at a dose of 105 mg/m2 with G-CSF support, which provides a dose-intensity of 52.5 mg/m2/wk. ...A formal phase II trial is needed to estimate better the true response rate....
CONCLUSION: LED can be administered every 2 weeks at a dose of 105 mg/m2 with G-CSF support, which provides a dose-intensity o …
Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma.
Casper ES, Schwartz GM, Leung D, Sugarman A, Bertino JR. Casper ES, et al. Sarcoma. 1999;3(2):121-7. doi: 10.1080/13577149977758. Sarcoma. 1999. PMID: 18521274 Free PMC article.
Forty-one patients with metastatic or unresectable, locally advanced sarcoma participated in this 2-step phase I trial.The starting dose of ifosfamide was 10 gm/m(2) given by continuous intravenous infusion over 4 days every 2 weeks.When the MTD was defined, edatrexate, beginning …
Forty-one patients with metastatic or unresectable, locally advanced sarcoma participated in this 2-step phase I trial.The starting dose of …
Phase II trial of paclitaxel in patients with soft-tissue sarcoma.
Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ilson D, Woodruff J, Leung D, Bertino JR. Casper ES, et al. Cancer Invest. 1998;16(7):442-6. doi: 10.3109/07357909809011697. Cancer Invest. 1998. PMID: 9774950 Clinical Trial.
Paclitaxel is clinically useful in treating several solid tumors and has demonstrated activity in a series of human sarcoma cell lines. ...The other PR occurred in a woman with metastatic uterine leiomyosarcoma and lasted 9 months. Seven patients had stable disease …
Paclitaxel is clinically useful in treating several solid tumors and has demonstrated activity in a series of human sarcoma cell line …
The attentional repulsion effect and relative size judgments.
Fortenbaugh FC, Sugarman A, Robertson LC, Esterman M. Fortenbaugh FC, et al. Among authors: sugarman a. Atten Percept Psychophys. 2019 Feb;81(2):442-461. doi: 10.3758/s13414-018-1612-x. Atten Percept Psychophys. 2019. PMID: 30488191 Free PMC article.
RGC-32 regulates reactive astrocytosis and extracellular matrix deposition in experimental autoimmune encephalomyelitis.
Tatomir A, Tegla CA, Martin A, Boodhoo D, Nguyen V, Sugarman AJ, Mekala A, Anselmo F, Talpos-Caia A, Cudrici C, Badea TC, Rus V, Rus H. Tatomir A, et al. Among authors: sugarman aj. Immunol Res. 2018 Aug;66(4):445-461. doi: 10.1007/s12026-018-9011-x. Immunol Res. 2018. PMID: 30006805 Free PMC article.
SIRT1 is decreased during relapses in patients with multiple sclerosis.
Tegla CA, Azimzadeh P, Andrian-Albescu M, Martin A, Cudrici CD, Trippe R 3rd, Sugarman A, Chen H, Boodhoo D, Vlaicu SI, Royal W 3rd, Bever C, Rus V, Rus H. Tegla CA, et al. Among authors: sugarman a. Exp Mol Pathol. 2014 Apr;96(2):139-48. doi: 10.1016/j.yexmp.2013.12.010. Epub 2014 Jan 5. Exp Mol Pathol. 2014. PMID: 24397908
Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.
Vlaicu SI, Tegla CA, Cudrici CD, Danoff J, Madani H, Sugarman A, Niculescu F, Mircea PA, Rus V, Rus H. Vlaicu SI, et al. Among authors: sugarman a. Immunol Res. 2013 May;56(1):109-21. doi: 10.1007/s12026-012-8381-8. Immunol Res. 2013. PMID: 23247987 Review.
The reluctance to self-disclose: reflexive or reasoned?
Sugarman A. Sugarman A. Psychoanal Q. 2012 Jul;81(3):627-55. doi: 10.1002/j.2167-4086.2012.tb00512.x. Psychoanal Q. 2012. PMID: 23038902
43 results
Jump to page
Feedback